天然产物研究与开发 ›› 2026, Vol. 38 ›› Issue (2): 262-272.doi: 10.16333/j.1001-6880.2026.2.004 cstr: 32307.14.1001-6880.2026.2.004

• 研究论文 • 上一篇    下一篇

红景天苷调节FOXO3-FOXM1信号轴对卵巢癌细胞化疗耐药性的影响

姜波玲1,冯  春2,郑  嵘2*   

  1. 1武汉市武昌区妇幼保健院,武汉 430000;2湖北省妇幼保健院,武汉 430070
  • 出版日期:2026-02-26 发布日期:2026-02-25
  • 基金资助:
    国家自然科学基金(82001644)

Effects of salidroside on chemotherapy resistance in ovarian cancer cells by regulating FOXO3-FOXM1 signaling axis

JIANG Bo-ling1,FENG Chun2,ZHENG Rong2*   

  1. 1Wuhan Wuchang Maternal and Child Health Hospital,Wuhan 430000,China;2Hubei Maternal and Child Health Hospital,Wuhan 430070,China
  • Online:2026-02-26 Published:2026-02-25

摘要:

探讨红景天苷(salidroside,SAL)调节叉头框蛋白O3(forkhead box protein O3,FOXO3)-叉头蛋白M1(forkhead box M1,FOXM1)信号轴对卵巢癌细胞化疗耐药性的影响。取对数期生长SKOV3细胞及卵巢癌顺铂(cisplatin,DDP)耐药细胞株SKOV3/DDP细胞。将SKOV3细胞分为正常对照组(正常培养)、SAL低、中、高剂量组(分别用40、80、160 μg/mL SAL干预)、sh-FOXO3组(转染sh-FOXO3质粒)、SAL + sh-FOXO3组(sh-FOXO3转染后再用160 μg/mL SAL处理);将SKOV3/DDP细胞分为SKOV3/DDP组(不做处理)、DDP组(0.3 μmol/L)、SAL+DDP组(0.3 μmol/L DDP和160 μg/mL SAL联合处理)、SAL + DDP + sh-FOXO3组(0.3 μmol/L DDP和160 μg/mL SAL联合处理并转染sh-FOXO3)。CCK-8法及平板克隆实验检测各组细胞增殖能力,流式细胞术、Transwell实验分别检测各组细胞凋亡及迁移能力。RT-qPCR法、Western blot分别测定FOXO3、FOXM1 mRNA和蛋白表达。免疫组化法测定卵巢癌患者癌组织和癌旁组织中FOXO3、FOXM1表达。结果显示,与正常对照组比较,SAL低、中、高剂量组细胞增殖率、迁移细胞数、集落形成数及FOXM1蛋白表达均降低,凋亡率及FOXO3蛋白表达均升高,且上述指标均呈SAL浓度依赖性变化,sh-FOXO3组细胞增殖率、迁移细胞数、集落形成数及FOXM1蛋白表达均升高,凋亡率及FOXO3蛋白表达均降低(P < 0.05)。与SAL高剂量组对比,SAL + sh-FOXO3组SKOV3细胞增殖率、迁移细胞数、集落形成数及FOXM1蛋白表达均升高,凋亡率及FOXO3蛋白表达均降低(P < 0.05)。分别与SKOV3/DDP组、DDP组对比,SAL + DDP组细胞增殖率、迁移细胞数、集落形成数及FOXM1蛋白表达均降低,凋亡率及FOXO3蛋白表达升高(P<0.05);对比SAL + DDP组,SAL + DDP + sh-FOXO3组凋亡率及FOXO3蛋白表达降低,上述剩余指标均升高(P 0.05)。卵巢癌组织中FOXO3(81.25%)阳性表达率高于癌旁组织(25.00%),FOXM1(14.58%)阳性表达率低于癌旁组织(77.08%)(P < 0.05)。综上所述,SAL可通过激活FOXO3-FOXM1信号而抑制卵巢癌细胞增殖、迁移和化疗敏感性,提高卵巢癌细胞对DDP的化疗耐药性。

关键词: 红景天苷, FOXO3-FOXM1, 卵巢癌, 增殖, 迁移, 化疗耐药性

Abstract:

This study aims to investigate the effect of salidroside (SAL) on the proliferation, migration, and chemoresistance of ovarian cancer cells by regulating the forkhead box O3 (FOXO3)-forkhead box M1 (FOXM1) signaling axis. SKOV3 cells in logarithmic growth phase and cisplatin (DDP)-resistant ovarian cancer cell line SKOV3/DDP cells were selected. The SKOV3 cells were divided into the normal control group (cultured under normal conditions), the SAL low-dose, medium-dose and high-dose groups (intervened with 40, 80, and 160 μg/mL SAL respectively), the sh-FOXO3 group (transfected with the sh-FOXO3 plasmid), and the SAL + sh-FOXO3 group (treated with 160 μg/mL SAL after sh-FOXO3 transfection). The SKOV3/DDP cells were divided into the SKOV3/DDP group (without any treatment), the DDP group (0.3 μmol/L), the SAL+DDP group (treated with 0.3 μmol/L DDP and 160 μg/mL SAL in combination), and the SAL + DDP + sh-FOXO3 group (treated with 0.3 μmol/L DDP and 160 μg/mL SAL in combination and transfected with sh-FOXO3). CCK-8 assay and plate cloning assay were used to detect cell proliferation, and flow cytometry and Transwell assay were used to detect cell apoptosis and migration. The mRNA and protein expressions of FOXO3 and FOXM1 were determined by RT-qPCR and Western blot, respectively. The expression of FOXO3 and FOXM1 in the cancer tissues and adjacent tissues of ovarian cancer patients was determined by immunohistochemical method. The results showed that compared with the normal control group, the cell proliferation rate, number of migrated cells, number of colony formations, and FOXM1 protein expression in L-SAL group, M-SAL group and H-SAL group were decreased, while the apoptosis rate and FOXO3 protein expression were increased. Moreover, all these indicators showed a SAL concentration-dependent changes with the SAL concentration. In the sh-FOXO3 group, the cell proliferation rate, the number of migrating cells, the number of colony formation and the expression of FOXM1 protein in the sh-FOXO3 group were all increased, while the apoptosis rate and the expression of FOXO3 protein were both decreased (P < 0.05). Compared with the SAL high-dose group, the proliferation rate, number of migrated cells, number of colony formations, and the expression of FOXM1 protein in SKOV3 cells in the SAL + sh-FOXO3 group were all increased, while the apoptosis rate and FOXO3 protein expression were both decreased (P < 0.05). Compared with the SKOV3/DDP group and DDP group respectively, the proliferation rate of SKOV3 cells, scratch healing rate, colony formation number, and FOXM1 protein expression decreased in the SAL + DDP group, while the apoptosis rate and FOXO3 protein expression increased (P < 0.05); compared with the SAL + DDP group, the apoptosis rate and FOXO3 protein expression of SAL + DDP + sh-FOXO3 group were decreased, while the remaining indicators mentioned above all increased (P < 0.05). The positive expression rate of FOXO3 in ovarian cancer tissues (81.25%) was higher than that in adjacent tissues (25.00%), while the positive expression rate of FOXM1 in cancer tissues (14.58%) was lower than that in adjacent tissues (77.08%) (P < 0.05). In summary, SAL can inhibit the proliferation, migration, and chemosensitivity of ovarian cancer cells, and enhance the chemoresistance of ovarian cancer cells to DDP by activating the FOXO3-FOXM1 signaling pathway.

Key words: salidroside, FOXO3-FOXM1, ovarian cancer, proliferation, migration, chemotherapy resistance

中图分类号:  R273